In both databases using only the GBM cohort, the STAT3 functionally tuned gene signature stratified survival and significantly enriched for the IDH-WT (wild-type) status, suggesting that the latter could act as a clinical molecular indicator for administering STAT3 inhibition therapy (Supplementary Table 1). The gene discussed is IDH2; the disease is glioblastoma.